速度向量成像技术评价表阿霉素复合药物所致早期心肌损害

目的: 应用速度向量成像技术(velocity vector imaging,VVI)检测表阿霉素对乳腺癌患者左室长轴收缩功能及舒张功能的影响及其临床价值。方法: 选取接受表阿霉素化疗的乳腺癌患者和正常对照组各30例,所有受检者于超声心动图中取心尖左室长轴、四腔心及两腔心切面的动态图像,脱机分析,获取每个受检者各节段长轴方向收缩期和舒张期各参数:收缩期峰值速度(Vs)、收缩期峰值应变(SS)及收缩期峰值应变率(SSR);舒张期峰值速度(Vd)、舒张期峰值应变率(DSR);每一指标均取两个心动周期的平均值。所有受检者同时接受常规超声的检测。结果: 化疗前30例乳腺癌患者与正常对照组相比,各指标差异无统计学意义(P>0.05)。在2个疗程化疗后,乳腺癌患者组DSR左室各室壁较患者基线水平明显减低(P<0.05),Vd左室游离壁(主要是后壁、侧壁及前壁)减低明显(P<0.05),而室间隔减低不明显(P>0.05)。在3个疗程化疗后,Vd,DSR及SSR左室各室壁较患者基线水平均减低明显(P<0.05),而Vs及SS减低不明显(P>0.05)。结论: VVI技术能早期监测表阿霉素对乳腺癌患者所致心肌损害,比常规超声心动图检查敏感。

Velocity vector imaging assessment of early epirubicin-induced myocardial damage

Objective: To assess the left ventricular (LV) longitudinal systolic and diastolic function in patients treated by epirubicin by velocity vector imaging (VVI) and to discuss the important clinical value of VVI in quantitatively evaluating the regional longitudinal function.
Methods: Thirty patients with breast cancer treated with epirubicin chemotherapy and 30 normal controls were included in the study. Dynamic images of apical long axis, four-chamber and two-chamber view were obtained in all subjects, and the longitudinal systolic and diatolic parameters were measured in all subjects, including systolic maximum velocity (Vs), systolic maximum strain (SS), systolic maximum strain rate (SSR), diastolic maximum velocity (Vd), and diastolic maximum strain rate (DSR). The parameters were compared between the 2 groups. The conventional echcardiographic parameters were also obtained.
Results: There was no significant change in all baseline parameters before the chemotherapy in 30 breast cancer patients compared with the normal controls (P>0.05). After the second chemotherapy cycle, DSR was lower in every segment, Vd was lower in the free wall, mainly the lateral, anterior and inferior wall (P<0.05), while Vd didn't change significantly in the septum wall (P>0.05). After the third chemotherapy cycle, Vd, DSR and SSR decreased significantly in all segments (P<0.05). Vs and SS didn't change significantly (P>0.05).
Conclusion: VVI can monitor the epirubicin cardiotoxicity early and is more sensitive than echocardiograph.